Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults

Abrahim Abduelmula; Brian D Rankin; Asfandyar Mufti; Jensen Yeung; Vimal H Prajapati

Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults

Skin Therapy Lett. 2023 Jan;28(1):1-6.

Authors

Abrahim Abduelmula¹, Brian D Rankin², Asfandyar Mufti³, Jensen Yeung^{4

5

6}, Vimal H Prajapati^{2

6

7

8

9

10}

Affiliations

¹ Faculty of Medicine, University of Western Ontario, London, ON, Canada.
² Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
³ Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.
⁴ Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
⁵ Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
⁶ Probity Medical Research, Waterloo, ON, Canada.
⁷ Dermatology Research Institute, Calgary, AB, Canada.
⁸ Skin Health & Wellness Centre, Calgary, AB, Canada.
⁹ Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
¹⁰ Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada.

PMID: 36657434

Abstract

Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.

Keywords: Adtralza; atopic dermatitis; biologic; clinical trial; eczema; immunomodulator; therapeutics; tralokinumab.

Copyright 2023 by SkinCareGuide.com Ltd. Skin Therapy Letter© is published 6 times annually by SkinCareGuide.com Ltd, 1003 - 1166 Alberni Street, Vancouver, British Columbia, Canada, V6E 3Z3. All rights reserved. Reproduction in whole or in part by any process is strictly forbidden without prior consent of the publisher in writing.

Publication types

Review

MeSH terms

Adult
Antibodies, Monoclonal
Dermatitis, Atopic* / drug therapy
Humans
Severity of Illness Index
Skin
Treatment Outcome

Substances

tralokinumab
Antibodies, Monoclonal